In patients with WT KRAS tumors , panitumumab-FOLFIRI significantly improved PFS versus FOLFIRI -LSB- median @ versus @ months ; hazard ratio ( HR ) @ -LSB- @ % confidence interval ( CI ) @ , @ -RSB- ; P = @ -RSB- .